<?xml version="1.0" encoding="UTF-8"?>
<!-- This sitemap was dynamically generated on May 12, 2026 at 7:46 AM by All in One SEO v4.9.6.2 - the original SEO plugin for WordPress. -->

<?xml-stylesheet type="text/xsl" href="https://cgxpwire.com/default-sitemap.xsl"?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>cGxP.wire</title>
		<link><![CDATA[https://cgxpwire.com]]></link>
		<description><![CDATA[cGxP.wire]]></description>
		<lastBuildDate><![CDATA[Tue, 12 May 2026 07:38:58 +0000]]></lastBuildDate>
		<docs>https://validator.w3.org/feed/docs/rss2.html</docs>
		<atom:link href="https://cgxpwire.com/sitemap.rss" rel="self" type="application/rss+xml" />
		<ttl><![CDATA[60]]></ttl>

		<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/roche-gains-ce-mark-approval-for-elecsys-ptau217-test/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/roche-gains-ce-mark-approval-for-elecsys-ptau217-test/]]></link>
			<title>Roche Gains CE Mark Approval for Elecsys pTau217 Test</title>
			<pubDate><![CDATA[Tue, 12 May 2026 07:38:58 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/novo-nordisk-reports-28-weight-loss-with-higher-dose-wegovy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/novo-nordisk-reports-28-weight-loss-with-higher-dose-wegovy/]]></link>
			<title>Novo Nordisk Reports 28% Weight Loss With Higher-Dose Wegovy</title>
			<pubDate><![CDATA[Tue, 12 May 2026 07:29:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/caris-life-sciences-shows-wes-improves-immunotherapy-survival-prediction/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/caris-life-sciences-shows-wes-improves-immunotherapy-survival-prediction/]]></link>
			<title>Caris Life Sciences Shows WES Improves Immunotherapy Survival Prediction</title>
			<pubDate><![CDATA[Tue, 12 May 2026 07:10:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/henlius-wins-u-s-fda-ind-clearance-for-hlx05-n/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/henlius-wins-u-s-fda-ind-clearance-for-hlx05-n/]]></link>
			<title>Henlius Wins U.S. FDA IND Clearance for HLX05-N</title>
			<pubDate><![CDATA[Tue, 12 May 2026 07:03:49 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/bristol-myers-squibb-secures-eu-approval-for-sotyktu-in-psoriatic-arthritis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/bristol-myers-squibb-secures-eu-approval-for-sotyktu-in-psoriatic-arthritis/]]></link>
			<title>Bristol Myers Squibb Secures EU Approval for Sotyktu in Psoriatic Arthritis</title>
			<pubDate><![CDATA[Tue, 12 May 2026 07:00:52 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/pulsesight-reports-positive-phase-1-results-for-pst-611/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/pulsesight-reports-positive-phase-1-results-for-pst-611/]]></link>
			<title>PulseSight Reports Positive Phase 1 Results for PST-611</title>
			<pubDate><![CDATA[Tue, 12 May 2026 06:38:21 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/government/fda-expands-drug-repurposing-initiative-for-rare-diseases/]]></guid>
			<link><![CDATA[https://cgxpwire.com/government/fda-expands-drug-repurposing-initiative-for-rare-diseases/]]></link>
			<title>FDA Expands Drug Repurposing Initiative for Rare Diseases</title>
			<pubDate><![CDATA[Tue, 12 May 2026 06:30:42 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/atyr-pharma-advances-efzofitimod-phase-3-sarcoidosis-program/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/atyr-pharma-advances-efzofitimod-phase-3-sarcoidosis-program/]]></link>
			<title>aTyr Pharma Advances Efzofitimod Phase 3 Sarcoidosis Program</title>
			<pubDate><![CDATA[Tue, 12 May 2026 06:15:12 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/apnimed-highlights-phase-3-ad109-osa-data-at-ats-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/apnimed-highlights-phase-3-ad109-osa-data-at-ats-2026/]]></link>
			<title>Apnimed Highlights Phase 3 AD109 OSA Data at ATS 2026</title>
			<pubDate><![CDATA[Tue, 12 May 2026 06:03:07 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/johnson-johnson-showcases-neuropsychiatry-data-at-apa-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/johnson-johnson-showcases-neuropsychiatry-data-at-apa-2026/]]></link>
			<title>Johnson &amp; Johnson Showcases Neuropsychiatry Data at APA 2026</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:52:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/dark-horse-consulting-and-kuntuo-partner-to-accelerate-cgt-trials/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/dark-horse-consulting-and-kuntuo-partner-to-accelerate-cgt-trials/]]></link>
			<title>Dark Horse Consulting and KunTuo Partner to Accelerate CGT Trials</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:44:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/partner-therapeutics-strengthens-oncology-portfolio-with-bizengri/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/partner-therapeutics-strengthens-oncology-portfolio-with-bizengri/]]></link>
			<title>Partner Therapeutics Strengthens Oncology Portfolio With BIZENGRI</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:40:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corvention-wins-fda-clearance-for-kardiapsi-balloon/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/corvention-wins-fda-clearance-for-kardiapsi-balloon/]]></link>
			<title>Corvention Wins FDA Clearance for KardiaPSI Balloon</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:35:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/myrtelle-presents-myr-101-canavan-disease-data-at-asgct-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/myrtelle-presents-myr-101-canavan-disease-data-at-asgct-2026/]]></link>
			<title>Myrtelle Presents MYR-101 Canavan Disease Data at ASGCT 2026</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:43:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/vasa-therapeutics-highlights-vs-214-at-aha-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/vasa-therapeutics-highlights-vs-214-at-aha-2026/]]></link>
			<title>Vasa Therapeutics Highlights VS-214 at AHA 2026</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:23:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/gsk-partners-with-sbp-group-to-expand-hepatitis-b-treatment/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/gsk-partners-with-sbp-group-to-expand-hepatitis-b-treatment/]]></link>
			<title>GSK Partners With SBP Group to Expand Hepatitis B Treatment</title>
			<pubDate><![CDATA[Tue, 12 May 2026 05:13:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/innovent-secures-third-nmpa-breakthrough-status-for-ibi363/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/innovent-secures-third-nmpa-breakthrough-status-for-ibi363/]]></link>
			<title>Innovent Secures Third NMPA Breakthrough Status for IBI363</title>
			<pubDate><![CDATA[Tue, 12 May 2026 04:51:51 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/transpire-bio-gains-fda-acceptance-for-high-strength-generic-trelegy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/transpire-bio-gains-fda-acceptance-for-high-strength-generic-trelegy/]]></link>
			<title>Transpire Bio Gains FDA Acceptance for High-Strength Generic Trelegy</title>
			<pubDate><![CDATA[Tue, 12 May 2026 04:45:54 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/nanoscope-therapeutics-highlights-mco-010-vision-data-at-asgct-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/nanoscope-therapeutics-highlights-mco-010-vision-data-at-asgct-2026/]]></link>
			<title>Nanoscope Therapeutics Highlights MCO-010 Vision Data at ASGCT 2026</title>
			<pubDate><![CDATA[Tue, 12 May 2026 04:42:43 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/veterinary/kingdom-reports-positive-dog-gut-health-study-results/]]></guid>
			<link><![CDATA[https://cgxpwire.com/veterinary/kingdom-reports-positive-dog-gut-health-study-results/]]></link>
			<title>Kingdom Reports Positive Dog Gut Health Study Results</title>
			<pubDate><![CDATA[Tue, 12 May 2026 04:37:36 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/persistent-launches-ai-innovation-lab-with-iit-kharagpur/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/persistent-launches-ai-innovation-lab-with-iit-kharagpur/]]></link>
			<title>Persistent Launches AI Innovation Lab With IIT Kharagpur</title>
			<pubDate><![CDATA[Sat, 09 May 2026 07:28:05 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/mission-bio-unveils-single-cell-crispr-t-cell-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/mission-bio-unveils-single-cell-crispr-t-cell-data/]]></link>
			<title>Mission Bio Unveils Single-Cell CRISPR T Cell Data</title>
			<pubDate><![CDATA[Sat, 09 May 2026 07:02:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/alpha-tau-completes-enrollment-in-pivotal-restart-cscc-study/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/alpha-tau-completes-enrollment-in-pivotal-restart-cscc-study/]]></link>
			<title>Alpha Tau Completes Enrollment in Pivotal ReSTART cSCC Study</title>
			<pubDate><![CDATA[Mon, 11 May 2026 07:46:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/actio-biosciences-initiates-kyron-phase-1b-2-trial-for-kcnt1-related-epilepsy/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/actio-biosciences-initiates-kyron-phase-1b-2-trial-for-kcnt1-related-epilepsy/]]></link>
			<title>Actio Biosciences Initiates KYRON Phase 1b/2 Trial for KCNT1-Related Epilepsy</title>
			<pubDate><![CDATA[Mon, 11 May 2026 07:31:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/alx-oncology-reports-durable-her2-breast-cancer-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/alx-oncology-reports-durable-her2-breast-cancer-data/]]></link>
			<title>ALX Oncology Reports Durable HER2 Breast Cancer Data</title>
			<pubDate><![CDATA[Sat, 09 May 2026 07:10:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/government/fda-releases-pregnancy-safety-guidance-for-drugs-and-biologics/]]></guid>
			<link><![CDATA[https://cgxpwire.com/government/fda-releases-pregnancy-safety-guidance-for-drugs-and-biologics/]]></link>
			<title>FDA Releases Pregnancy Safety Guidance for Drugs and Biologics</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:52:15 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/technology/persistent-strengthens-life-sciences-ai-through-databricks/]]></guid>
			<link><![CDATA[https://cgxpwire.com/technology/persistent-strengthens-life-sciences-ai-through-databricks/]]></link>
			<title>Persistent Strengthens Life Sciences AI Through Databricks</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:41:55 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/halozyme-and-gsk-partner-on-next-gen-adc-cancer-therapies/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/halozyme-and-gsk-partner-on-next-gen-adc-cancer-therapies/]]></link>
			<title>Halozyme and GSK Partner on Next-Gen ADC Cancer Therapies</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:27:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/mabwell-wins-fda-ind-clearance-for-9mw5211-in-ibd/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/mabwell-wins-fda-ind-clearance-for-9mw5211-in-ibd/]]></link>
			<title>Mabwell Wins FDA IND Clearance for 9MW5211 in IBD</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:12:47 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/argenx-gains-fda-approval-expanding-vyvgart-to-all-gmg-patients/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/argenx-gains-fda-approval-expanding-vyvgart-to-all-gmg-patients/]]></link>
			<title>Argenx Gains FDA Approval Expanding VYVGART to All gMG Patients</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:08:45 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/government/fda-approves-bizengri-for-rare-cholangiocarcinoma/]]></guid>
			<link><![CDATA[https://cgxpwire.com/government/fda-approves-bizengri-for-rare-cholangiocarcinoma/]]></link>
			<title>FDA Approves Bizengri for Rare Cholangiocarcinoma</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:45:23 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/alpha-tau-moves-closer-to-fda-clearance-for-alpha-dart/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/alpha-tau-moves-closer-to-fda-clearance-for-alpha-dart/]]></link>
			<title>Alpha Tau Moves Closer to FDA Clearance for Alpha DaRT</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:37:22 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/ensoma-presents-initial-en-374-clinical-safety-data-at-asgct-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/ensoma-presents-initial-en-374-clinical-safety-data-at-asgct-2026/]]></link>
			<title>Ensoma Presents Initial EN-374 Clinical Safety Data at ASGCT 2026</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:31:18 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/mergers-acquisitions/medit-enters-new-growth-phase-with-progressive-orthodontics/]]></guid>
			<link><![CDATA[https://cgxpwire.com/mergers-acquisitions/medit-enters-new-growth-phase-with-progressive-orthodontics/]]></link>
			<title>Medit Enters New Growth Phase With Progressive Orthodontics</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:25:14 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/servier-advances-ojemda-front-line-brain-cancer-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/servier-advances-ojemda-front-line-brain-cancer-trial/]]></link>
			<title>Servier Advances OJEMDA Front-Line Brain Cancer Trial</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:08:53 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/whiteswell-reports-positive-delta-hf-trial-results-for-elym-system-in-acute-heart-failure/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/whiteswell-reports-positive-delta-hf-trial-results-for-elym-system-in-acute-heart-failure/]]></link>
			<title>WhiteSwell Reports Positive DELTA-HF Trial Results for eLym System in Acute Heart Failure</title>
			<pubDate><![CDATA[Mon, 11 May 2026 05:06:57 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/inhibrx-reports-progress-for-inbrx-106-in-hnscc-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/inhibrx-reports-progress-for-inbrx-106-in-hnscc-trial/]]></link>
			<title>Inhibrx Reports Progress for INBRX-106 in HNSCC Trial</title>
			<pubDate><![CDATA[Mon, 11 May 2026 04:59:30 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/coretissue-bioengineering-initiates-randomized-acl-reconstruction-trial/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/coretissue-bioengineering-initiates-randomized-acl-reconstruction-trial/]]></link>
			<title>CoreTissue BioEngineering Initiates Randomized ACL Reconstruction Trial</title>
			<pubDate><![CDATA[Mon, 11 May 2026 04:56:40 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/aavnergene-unveils-high-yield-aavone2-1-platform/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/aavnergene-unveils-high-yield-aavone2-1-platform/]]></link>
			<title>AAVnerGene Unveils High-Yield AAVone®2.1 Platform</title>
			<pubDate><![CDATA[Mon, 11 May 2026 04:34:04 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/lumenis-folix-wins-2025-hair-loss-innovation-award/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/lumenis-folix-wins-2025-hair-loss-innovation-award/]]></link>
			<title>Lumenis FoLix Wins 2025 Hair Loss Innovation Award</title>
			<pubDate><![CDATA[Mon, 11 May 2026 04:22:11 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/eisai-and-biogen-receive-fda-extension-for-leqembi/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/eisai-and-biogen-receive-fda-extension-for-leqembi/]]></link>
			<title>Eisai and Biogen Receive FDA Extension for LEQEMBI</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:55:25 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/trexbio-reports-new-trb-061-data-for-atopic-dermatitis/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/trexbio-reports-new-trb-061-data-for-atopic-dermatitis/]]></link>
			<title>TRexBio Reports New TRB-061 Data for Atopic Dermatitis</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:50:00 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/azalea-therapeutics-unveils-first-ever-in-vivo-trac-car-t-cell-engineering-breakthrough-at-asgct-2026/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/azalea-therapeutics-unveils-first-ever-in-vivo-trac-car-t-cell-engineering-breakthrough-at-asgct-2026/]]></link>
			<title>Azalea Therapeutics Unveils First-Ever In Vivo TRAC-CAR T Cell Engineering Breakthrough at ASGCT 2026</title>
			<pubDate><![CDATA[Mon, 11 May 2026 07:14:29 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/biopharma/beacon-therapeutics-reports-positive-xlrp-gene-therapy-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/biopharma/beacon-therapeutics-reports-positive-xlrp-gene-therapy-data/]]></link>
			<title>Beacon Therapeutics Reports Positive XLRP Gene Therapy Data</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:47:13 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/biorestorative-therapies-reports-strong-phase-2-brtx-100-data/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/biorestorative-therapies-reports-strong-phase-2-brtx-100-data/]]></link>
			<title>BioRestorative Therapies Reports Strong Phase 2 BRTX-100 Data</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:31:35 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/pharma/incyte-opzelura-shows-durable-atopic-dermatitis-benefit/]]></guid>
			<link><![CDATA[https://cgxpwire.com/pharma/incyte-opzelura-shows-durable-atopic-dermatitis-benefit/]]></link>
			<title>Incyte Opzelura Shows Durable Atopic Dermatitis Benefit</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:29:33 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/caris-life-sciences-files-ny-approval-for-caris-assure/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/caris-life-sciences-files-ny-approval-for-caris-assure/]]></link>
			<title>Caris Life Sciences Files NY Approval for Caris Assure</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:49:34 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/bausch-lomb-bi-blade-boosts-retina-surgery-efficiency/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/bausch-lomb-bi-blade-boosts-retina-surgery-efficiency/]]></link>
			<title>Bausch + Lomb Bi-Blade+ Boosts Retina Surgery Efficiency</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:23:20 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/glucotrack-announces-fda-ide-submission-for-implantable-continuous-blood-glucose-monitoring-technology/]]></guid>
			<link><![CDATA[https://cgxpwire.com/medical-devices-diagnostics-radiation-emitting/glucotrack-announces-fda-ide-submission-for-implantable-continuous-blood-glucose-monitoring-technology/]]></link>
			<title>Glucotrack Announces FDA IDE Submission for Implantable Continuous Blood Glucose Monitoring Technology</title>
			<pubDate><![CDATA[Sat, 09 May 2026 06:19:26 +0000]]></pubDate>
		</item>
					<item>
			<guid><![CDATA[https://cgxpwire.com/clinical-trial-research/longeveron-reports-constructive-fda-meeting-ahead-of-elpis-ii-hlhs-data-readout/]]></guid>
			<link><![CDATA[https://cgxpwire.com/clinical-trial-research/longeveron-reports-constructive-fda-meeting-ahead-of-elpis-ii-hlhs-data-readout/]]></link>
			<title>Longeveron Reports Constructive FDA Meeting Ahead of ELPIS II HLHS Data Readout</title>
			<pubDate><![CDATA[Mon, 11 May 2026 06:40:36 +0000]]></pubDate>
		</item>
				</channel>
</rss>
